Geron posts Q1 net loss $38.1M; cash $409.2M; NDA on track for June 2023

GERON CORP

2023-Q1 EPS reported -$0.07 revenue$21,000

Net loss of $38.1M ($0.07/sh) vs $30.1M loss ($0.09/sh) in Q1 2022; revenue negligible.
Cash & marketable securities $409.2M; raised $213.3M from Jan 2023 offering plus $59.8M warrant exercises.
Planned U.S. NDA submission for imetelstat in lower-risk MDS on track for June 2023; potential launch H1 2024.
Reaffirmed FY2023 GAAP total expense guidance of $210M-$220M; non-GAAP $200M-$210M.
Cash runway projected through Q3 2025, supporting US/EU launches and IMpactMF Phase 3 trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GERON CORP reported the first quarter of 2023 results: revenue $21,000, net income $38.1 million, or $0.07 per share, EPS $0.07 per share. Guidance reaffirmed.

Period: the first quarter of 2023
Revenue: $21,000
Net income: $38.1 million, or $0.07 per share
EPS: $0.07 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

a net loss of $38.1 million, or $0.07 per share, compared to $30.1 million, or $0.09 per share, for the first quarter of 2022. Revenues for the first quarter of 2023 were $21,000 compared to $123,000 for the same period in 2022. Royalty revenues in 2023 and 2022 primarily reflect estimated royalties from sales of cell-based research products from the

View on SEC.gov

Browse all earnings releases →

GERON CORP filing history →

Source: SEC EDGAR

accession 0000950170-23-020860

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.